Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site
BOSTON– TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX), a global biotechnology company. The Vertex Cell and Genetic Therapies site will house the company’s research, development, and clinical manufacturing activities for cell and genetic therapies – two rapidly emerging therapeutic modalities with the potential to treat—and even cure—several of the diseases Vertex is focused on. TRIA was selected to provide architectural services for the design and build-out of laboratory, office, and amenity spaces for Vertex’s newly constructed 268,000 SF research site.